-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with atrial fibrillation (AF) have a five-fold increased risk of stroke
.
However, risk varies widely between patients and can be estimated using the CHA2DS2-VASc score
Consensus on the prevention of stroke CHA2DS2-VASc hypertension and vascular diabetes
Recently, a research article was published in Eur Heart J, an authoritative journal in the cardiovascular field.
The researchers conducted a multinational cohort study in Sweden, Denmark, Norway and Scotland
.
A total of 59 076 AF patients diagnosed with low stroke risk were included in the study
.
We used inverse probability weighted (IPTW) Cox regression to assess the incidence of stroke or major bleeding with or without treatment with a non-vitamin K antagonist oral anticoagulant (NOAC), vitamin K antagonist (VKA), or no treatment
diagnosis
In untreated patients, the rate of ischemic stroke was 0.
70 per 100 person-years and the rate of bleeding was 0.
70 per 100 person-years
.
Compared with no NOAC treatment, NOAC treatment was associated with a lower incidence of stroke [hazard ratio (HR), 0.
These observational data suggest that NOAC therapy may confer a positive net clinical benefit compared with no treatment or VKA in patients at lower stroke risk, an issue that can be tested in randomized controlled trials
.
.
Original source:
Original source:Joris J.
Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
